Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL.
With over 16 years of experience and knowledge in ADC innovation, Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
Help employers find you! Check out all the jobs and post your resume.
